EHC

Encompass Health Corporation (EHC) receives a #2 (Buy) rating on the Zacks Rank with a VGM Score of A. The integrated healthcare services provider, operating 173 hospitals across 39 states and Puerto Rico, demonstrates strong growth potential with forecasted year-over-year earnings growth of 11.6% for fiscal 2026. Recent analyst revisions have increased the Zacks Consensus Estimate to $6.08 per share, with an average earnings surprise of +6.8%.

Zacks identifies Encompass Health (EHC) as an attractive value stock with a Zacks Rank #2 (Buy) rating and an 'A' Value grade. The company's P/B ratio of 4.12 and P/CF ratio of 14.97 are both favorable compared to industry averages, suggesting the stock is undervalued relative to its earnings outlook and cash flow.

Encompass Health Corporation (EHC) has been highlighted as a stock to watch with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company, a provider of integrated healthcare services with 173 hospitals across 39 states and Puerto Rico, benefits from growing demand for coordinated care models. Recent analyst revisions have increased fiscal 2026 earnings estimates to $6.08 per share, with the stock showing an average earnings surprise of +6.8%.

Encompass Health Corporation (EHC) opened its first wholly owned hospital in Maine with 50 inpatient rehabilitation beds. Q2 2026 discharges rose 5.6% year-over-year, driven by new capacity and 2.8% same-store growth. EHC opened three hospitals in the first half of 2026 and plans to open eight new hospitals throughout the year, reflecting its strategy to expand capacity in favorable markets.

Encompass Health (EHC) is presented as a potential growth investment pick with a #3 (Hold) Zacks Rank and an A VGM Score. The company, which operates 173 inpatient rehabilitation hospitals across 39 states and Puerto Rico, shows strong growth prospects with forecasted year-over-year earnings growth of 11.6% for fiscal 2026. Seven analysts have raised earnings estimates in the last 60 days, with the consensus estimate increasing to $6.08 per share and an average earnings surprise of +6.8%.

Zacks recommends two Madison Small Cap mutual funds (BVAOX and MSCIX) as strong buy options for long-term investors. Both funds focus on undervalued U.S. small-cap companies with market capitalizations under $2 billion, offering positive three and five-year returns with expense ratios below category averages.